rs80055610

Variant summary

Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM5PP2PP3_StrongPP5_Very_Strong

The NM_000492.4(CFTR):​c.1679G>A​(p.Arg560Lys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000998 in 1,402,616 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R560T) has been classified as Pathogenic.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.000010 ( 0 hom. )

Consequence

CFTR
NM_000492.4 missense, splice_region

Scores

13
5
1
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic reviewed by expert panel P:8

Conservation

PhyloP100: 8.82

Publications

105 publications found
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
CFTR Gene-Disease associations (from GenCC):
  • cystic fibrosis
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, Orphanet
  • congenital bilateral absence of vas deferens
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary chronic pancreatitis
    Inheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 17 ACMG points.

PM1
In a hotspot region, there are 14 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 19 uncertain in NM_000492.4
PM5
Other missense variant is known to change same aminoacid residue: Variant chr7-117587833-G-C is described in ClinVar as Pathogenic. ClinVar VariationId is 7113.Status of the report is practice_guideline, 4 stars.
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 197 curated pathogenic missense variants (we use a threshold of 10). The gene has 46 curated benign missense variants. Gene score misZ: -3.1397 (below the threshold of 3.09). Trascript score misZ: -1.0868 (below the threshold of 3.09). GenCC associations: The gene is linked to hereditary chronic pancreatitis, cystic fibrosis, congenital bilateral absence of vas deferens.
PP3
Splicing predictors support a deleterious effect. Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 7-117587833-G-A is Pathogenic according to our data. Variant chr7-117587833-G-A is described in ClinVar as Pathogenic. ClinVar VariationId is 7156.Status of the report is reviewed_by_expert_panel, 3 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CFTRNM_000492.4 linkc.1679G>A p.Arg560Lys missense_variant, splice_region_variant Exon 12 of 27 ENST00000003084.11 NP_000483.3 P13569-1A0A024R730

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CFTRENST00000003084.11 linkc.1679G>A p.Arg560Lys missense_variant, splice_region_variant Exon 12 of 27 1 NM_000492.4 ENSP00000003084.6 P13569-1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
AF:
0.00000998
AC:
14
AN:
1402616
Hom.:
0
Cov.:
23
AF XY:
0.00000713
AC XY:
5
AN XY:
701596
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
32232
American (AMR)
AF:
0.00
AC:
0
AN:
44522
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25724
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39322
South Asian (SAS)
AF:
0.00
AC:
0
AN:
85100
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53354
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5672
European-Non Finnish (NFE)
AF:
0.0000132
AC:
14
AN:
1058278
Other (OTH)
AF:
0.00
AC:
0
AN:
58412
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.00
Hom.:
0

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:7
Jun 13, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The CFTR c.1679G>A (p.Arg560Lys) variant involves the alteration of a conserved nucleotide at the end of exon 12 and is located in P-loop containing nucleoside triphosphate hydrolase, AAA+ ATPase and/or ABC transporter 1 domain of the protein (InterPro). 4/5 in silico tools predict damaging outcome for this variant. In addition, 5/5 splice prediction tools predict that this variant weakens the canonical 5' splice donor site. This variant has been reported in several CF patients, majority of patients characterized to be pancreatic insufficient (Ferec_1992, Osika_1999, Scotet_2003, Sosnay_2013) and is absent in 118816 control chromosomes from ExAC. Functional analysis shows that this variant leads to defective chloride channel and/or CFTR processing (Sosnay_2013). Multiple clinical diagnostic laboratories/reputable databases have classified this variant as pathogenic. Other missense changes at the same residue, namely p.Arg560Gly, p.Arg560Ser, and p.Arg560Thr have been reported to associate with CF, indicating Arg560 is a mutational hot-spot. Taken together, this variant is classified as pathogenic. -

Mar 17, 2017
CFTR2
Significance:Pathogenic
Review Status:reviewed by expert panel
Collection Method:research

- -

Jun 16, 2022
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.R560K variant (also known as c.1679G>A), located in coding exon 12 of the CFTR gene, results from a G to A substitution at nucleotide position 1679. The arginine at codon 560 is replaced by lysine, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 12, which makes it likely to have some effect on normal mRNA splicing. This variant has been reported in multiple individuals with an elevated sweat chloride level in The Clinical and Functional TRanslation of CFTR (CFTR2) database (available at http://cftr2.org. Accessed 06/16/2022). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. This amino acid position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition, as a missense substitution this is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Jan 04, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 560 of the CFTR protein (p.Arg560Lys). This variant also falls at the last nucleotide of exon 12, which is part of the consensus splice site for this exon. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with cystic fibrosis (PMID: 23974870). ClinVar contains an entry for this variant (Variation ID: 7156). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts the p.Arg560 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15371902, 23974870). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -

Jan 29, 2018
CFTR-France
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Jun 01, 1992
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Apr 16, 2018
Counsyl
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Jan 03, 2023
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.79
BayesDel_addAF
Pathogenic
0.53
D
BayesDel_noAF
Pathogenic
0.52
CADD
Pathogenic
34
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.95
D;.;D;.
Eigen
Pathogenic
1.0
Eigen_PC
Pathogenic
0.95
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Uncertain
0.89
D;D;D;D
M_CAP
Pathogenic
0.69
D
MetaRNN
Pathogenic
0.99
D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.1
M;.;.;.
PhyloP100
8.8
PrimateAI
Uncertain
0.70
T
PROVEAN
Uncertain
-2.8
D;.;D;.
REVEL
Pathogenic
0.94
Sift
Pathogenic
0.0
D;.;D;.
Sift4G
Uncertain
0.012
D;.;D;.
Polyphen
1.0
D;.;.;.
Vest4
0.94
MutPred
0.99
Loss of methylation at R560 (P = 0.0407);.;.;.;
MVP
1.0
MPC
0.017
ClinPred
1.0
D
GERP RS
5.3
Varity_R
1.0
gMVP
0.99
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
1.0
SpliceAI score (max)
0.82
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.82
Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs80055610; hg19: chr7-117227887; API